Is suvorexant a better choice than alternative hypnotics?

Area of Science:

• Pharmacology
• Sleep Medicine
• Clinical Therapeutics

Background:

• Suvorexant is a novel dual orexin receptor antagonist (DORA) approved as a hypnotic.
• Concerns exist regarding the efficacy of FDA-recommended starting doses (5 and 10 mg) for suvorexant, as these were not fully evaluated in initial trials.
• Dose reductions for other hypnotics like zolpidem and eszopiclone suggest potential widespread issues with hypnotic effectiveness.

Purpose of the Study:

• To evaluate the efficacy and safety of suvorexant compared to existing hypnotics.
• To assess the benefits-to-risks ratio of suvorexant.
• To explore potential long-term safety advantages of suvorexant.

Main Methods:

• Analysis of manufacturer's Phase III trial data for suvorexant.
• Comparison of suvorexant's effects on sleep latency, wake after sleep onset, and sleep efficiency.
• Review of FDA concerns regarding higher suvorexant dosages (40 mg) and documented associations between hypnotic use and adverse health outcomes.

Main Results:

• Suvorexant (up to 20 mg) shows a modest effect on reducing nighttime awakenings and improving sleep efficiency, with minimal impact on sleep onset latency due to slow absorption.
• The FDA rejected the manufacturer's preferred 40 mg dose due to concerns about daytime somnolence and driving impairment.
• Suvorexant is unlikely to offer significant benefits over current hypnotics and may be more expensive with less real-world data.

Conclusions:

• Suvorexant's immediate benefits-to-risks profile does not suggest superiority over existing hypnotics, and it may even be less favorable.
• While suvorexant might theoretically offer safety advantages regarding cancer, dementia, and mortality, these remain unproven speculations requiring long-term clinical trials.
• Further research is necessary to validate any potential long-term safety benefits of suvorexant over alternative hypnotic medications.